Literature DB >> 8938683

Complete clinical remission and subsequent relapse of bronchiectasis-related (AA) amyloid induced nephrotic syndrome.

D J Goldsmith1, I S Roberts, C D Short, N P Mallick.   

Abstract

Systemic amyloidosis normally has a dismal prognosis. However, there are several case reports of protracted survival, usually as a response to measures designed to retard the further deposition of amyloid fibrils. In AA amyloid, most commonly associated with inflammatory rheumatological, bowel, and chest diseases, such interventions have had some success, but the dramatic response of complete resolution of nephrotic syndrome as a result of the regular institution of postural chest drainage and antibiotic therapy, in the clinical context of bronchiectasis, has been previously reported only once. In both of our cases, after protracted remission, such therapy was abandoned by the patients, leading both to recurrence of nephrotic syndrome and also eventually to end-stage renal failure requiring dialysis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938683     DOI: 10.1159/000189454

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  4 in total

1.  Hyperechoic kidneys in a patient with bronchiectasis.

Authors:  A G Umolu; R Venn; D Maxwell; Z Al Shiekh Ali; D C Howlett
Journal:  Ultrasound       Date:  2021-02-11

2.  A young patient with recurrent respiratory tract infection and anasarca.

Authors:  Kosar Hussain; Niaz Ahmed Shaikh; Liza Thomas; Mahmoud M Marashi
Journal:  BMJ Case Rep       Date:  2013-11-11

3.  Review of eprodisate for the treatment of renal disease in AA amyloidosis.

Authors:  Adam Rumjon; Thomas Coats; Muhammad M Javaid
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-02-24

4.  Unusual case of ATTR amyloidosis with cardiac manifestation and situs inversus totalis.

Authors:  Max Fritschka; Michael Schlegl; Adrian Borges; Mathias Werner; Rolf Gebker; Burkert Pieske; Sebastian Kelle
Journal:  Clin Res Cardiol       Date:  2017-01-23       Impact factor: 5.460

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.